Lorlatinib in ALK-positive advanced NSCLC: a real-world, multicenter study within a hub-and-spoke collaborative network across core and primary hospitals in China (ESMO Asia 2026) - Oct 1, 2026 - Abstract #996P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Puyuan Xing; Lige Wu; Junping Wei; Runfu Li; Yun'an Liu; Ping Lu; Shaoshan Zeng; Yanan Zhang; Jiayu Liu; Shouzheng Wang; Le Tang; Junling Li
|